azelastine + fluticasone

**Azelastine + fluticasone** is a fixed-dose intranasal combination of azelastine hydrochloride, a histamine H1-receptor antagonist, and fluticasone propionate, a synthetic glucocorticoid corticosteroid. It was developed as MP29-02 and marketed as Dymista, delivering 137 mcg azelastine hydrochloride and 50 mcg fluticasone propionate per spray in the US formulation. The combination provides rapid antihistamine-mediated control of histamine-driven nasal symptoms alongside glucocorticoid receptor-mediated suppression of allergic nasal inflammation. It is approved for symptomatic treatment of seasonal allergic rhinitis in adults and pediatric patients aged 6 years and older in the United States, with allergic rhinitis and perennial allergic rhinitis indications in other markets. ([accessdata.fda.gov](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/202236s021lbl.pdf))

Brand names

Dymista

Other names

AzeFluazelastine hydrochloride + fluticasone propionateazelastine hydrochloride and fluticasone propionateazelastine/fluticasonefluticasone + azelastinefluticasone propionate + azelastine hydrochlorideMP-AzeFlu